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ABSTRACT
Background: Mucin glycoprotein 1 (MUC1) is a glycosylated transmembrane 
protein on epithelial cells. We investigate MUC1 as a therapeutic target in Barrett’s 
epithelium (BE) and esophageal adenocarcinoma (EA) and provide proof of concept 
for a light based therapy targeting MUC1.
Results: MUC1 was present in 21% and 30% of significantly enriched pathways 
comparing BE and EA to squamous epithelium respectively. MUC1 gene expression was 
x2.3 and x2.2 higher in BE (p=<0.001) and EA (p=0.03). MUC1 immunohistochemical 
expression increased during progression to EA and followed tumor invasion. HuHMFG1 
based photosensitive antibody drug conjugates (ADC) showed cell internalization, 
MUC1 selective and light-dependent cytotoxicity (p=0.0006) and superior toxicity 
over photosensitizer alone (p=0.0022).
Methods: Gene set enrichment analysis (GSEA) evaluated pathways during BE 
and EA development and quantified MUC1 gene expression. Immunohistochemistry 
and flow cytometry evaluated the anti-MUC1 antibody HuHMFG1 in esophageal 
cells of varying pathological grade. Confocal microscopy examined HuHMFG1 
internalization and HuHMFG1 ADCs were created to deliver a MUC1 targeted 
phototoxic payload.
Conclusions: MUC1 is a promising target in EA. Molecular and light based targeting 
of MUC1 with a photosensitive ADC is effective in vitro and after development may 
enable treatment of locoregional tumors endoscopically.
INTRODUCTION
Despite progress in the treatment of other cancers, 
the 5-year survival of esophageal adenocarcinoma (EA) 
remains low at around 15% [1]. Barrett’s epithelium is a 
premalignant change that increases the risk of developing 
EA 30-100 fold above that for the general population [2, 
3]. Eradication of Barrett’s epithelium significantly reduces 
the risk of developing EA [4]. Identifying new therapeutic 
targets for Barrett’s epithelium and EA is of vital 
clinical importance. Within the field of esophagogastric 
adenocarcinoma HER2 is the only therapeutic biomarker 
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to be incorporated into widespread clinical practice. 
The HER2-targeting antibody Trastuzumab when used 
in combination with chemotherapy has been shown to 
improve progression-free and overall survival in HER2 
positive gastric and gastroesophageal junction cancer 
patients [5]. HER2 overexpression occurs in approximately 
13-23% of esophagogastric cancers but expression can be 
heterogeneous [6, 7]. An ideal therapeutic target would be 
stable and present in a higher proportion of tumors.
The mucin MUC1 is a densely glycosylated 
transmembrane protein anchored to the apical surface 
of many epithelia including the breast, ovary, pancreas, 
airway and gastrointestinal tract. The extracellular 
subunit of MUC1 has a ‘variable number tandem repeat’ 
(VNTR) region which consists of a repeating 20 amino 
acid sequence mediating heavy O-linked glycosylation 
[8]. MUC1 has an important extracellular role in cell 
surface lubrication and the clearance of debris and 
pathogens. Its intracellular signaling is linked to the ErbB, 
fibroblast growth factor receptor 3 and p53 pathways, 
which are implicated in cancer development [9]. MUC1 
is overexpressed in a diverse range of carcinomas. 
In progression to cancer, MUC1 protein expression 
generally increases, alters location and is coupled with 
aberrant glycosylation [8, 10]. Previous studies of 
MUC1 expression in the premalignant changes of EA are 
inconsistent [11–13]. Up-regulation of MUC1 has been 
linked to bile acids exposure in gastroesophageal reflux, 
a condition connected to the development of Barrett’s 
epithelium and EA [14]. Others have associated a single 
nucleotide polymorphism in the MUC1 gene to a reduced 
risk of other upper gastrointestinal cancers [15].
HuHMFG1 is an antibody against MUC1 that has 
been tested in clinical trials for breast cancer [16–18]. 
Targeting using HuHMFG1 was ineffective alone but the 
antibody was well tolerated and had a good safety profile 
[19]. Later studies used the radiolabeled anti-MUC1 
antibody (yttrium-90-AS1402) in ovarian cancer after 
de-bulking surgery. Administration led to endogenous 
production of anti-MUC1 IgG in some patients, but there 
was no survival benefit in those in whom this occurred 
[20]. HuHMFG1 undergoes cell internalization [21] 
and was considered as a vehicle for an antibody-drug 
conjugate (ADC) approach using the potent cytotoxin, 
calicheamycin. Reasonable efficacy was seen but in 
this example the overall therapeutic window was low 
as calicheamycin was not well tolerated at the higher 
doses [22]. ADCs are a well-established and clinically-
successful approach to cancer therapy but target and 
payload selection are key in developing drugs with high 
efficacy and tolerability, i.e. a high therapeutic index (TI). 
With the right payload, an anti MUC1 ADC could have 
great potential.
Photodynamic therapy (PDT) is an ideal modality 
for application to ADC, particularly where there is some 
degree of normal tissue expression and hence the TI is 
low. PDT is already an established treatment modality 
for dysplastic Barrett’s epithelium [23]. It has also shown 
utility in the treatment of cancers of the prostate, lung, 
pancreas, bile duct, oral cavity and skin [24, 25]. PDT 
involves the administration of a photosensitizer (PS) 
and its activation locally using light to cause cellular 
destruction via intracellular free radicals and/or reactive 
oxygen species [26–29]. As there is little effect on 
connective tissue, it preserves luminal integrity when 
used in the digestive tract [29]. Though not inherent to 
PDT itself, the first generation photosensitizers approved 
for clinical use such as porfimer sodium suffered from 
suboptimal pharmacokinetic / biodistribution profile and 
poor tumor selectivity. This led to low potency and off 
target photosensitivity, resulting in severe sunburn and the 
scarring of internal organs in some patients [23]. These 
limitations can be inherent to any therapeutic molecule 
but by chemical modification and/or combination with 
other molecules it is now possible to avoid them [30–
34]. Photoimmunotherapy is one such approach using 
a niche ADC where PS are targeted with antibodies 
(photoimmunoconjugates) [33, 35–38].
This study aims to highlight the role MUC1 plays 
in the progression to EA. It further examines how MUC1 
expression and glycosylation are altered during esophageal 
malignant transformation and later locoregional invasion. 
Finally proof of principle data for the mechanism and in 
vitro efficacy of a MUC1 targeting ADC using PDT is 
shown.
RESULTS
Identification of MUC1 as a biomarker in the 
development of EA
MUC1 was linked to the progression to EA using 
gene set enrichment analysis (GSEA). Within the GSEA 
two groups of upper GI samples were compared; the 
comparison of non-dysplastic Barrett's esophagus (NDBE) 
to normal esophageal squamous epithelium (Sq) gave 47 
pathways that were enriched in NDBE compared to Sq, 
of which 28 were significant and of these 21% included 
MUC1. Comparison of EA to Sq gave 49 pathways 
enriched in EA compared to Sq of which 27 pathways 
were significant and of these 30% included MUC1 
(Figure 1 and Supplementary Figure 1). This recurrent 
appearance of MUC1 in the significant pathways suggests 
involvement in the transition of normal esophageal tissue 
to malignancy. Some of the most significant pathways 
included both MUC1 and HER2. To see if the MUC1 
gene was up regulated during cancer progression the 
data was mined using the Affymetrix probe for MUC1 
to retrieve raw gene expression values. When compared 
to Sq, mRNA levels in NDBE show a 2.3 fold increase 
in MUC1 expression (p < 0.001), while mRNA levels in 
EA showed an increase in both the range of expression as 
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well as an overall 2.2 fold increase in MUC1 expression 
(p = 0.03) (Figure 1).
MUC1 glycoprotein tissue staining
Four antibodies against different epitopes of 
MUC1 (Figure 2) were used to stain patient samples 
representing various stages toward progression to cancer; 
Sq epithelium, NDBE, low-grade dysplasia (LGD), 
high grade dysplasia (HGD) and invasive esophageal 
adenocarcinoma (EA). HuHMFG1 immunostaining was 
mostly membranous and cytoplasmic with additional 
nuclear staining in highly expressing samples. CT2 and 
NCL-MUC-1 stained predominantly the apical membrane 
with mild cytoplasmic positivity. NCL-MUC-1-CORE 
staining was focused on the luminal surface of cells. In 
all cases binding was limited to the epithelial cell layer. 
The intensity of HuHMFG1 staining increased in the 
progression to EA, and towards the more differentiated 
superficial epithelial cells (Figure 3).
HuHMFG1 and CT2 binding increased from 
moderate in squamous mucosa to high levels in NDBE. 
NCL-MUC-1 and NCL-MUC-1-CORE maintained 
low binding levels in normal and dysplastic tissue but 
increased to high levels of binding in EA tissue (Figure 
4). An alternative representation (Supplementary 
Figure 2) shows the Allred score of individual samples 
and is presented to show the heterogeneity of all four 
antibodies across all pathological grades. Due to the 
recognized EA risk of dysplastic columnar epithelium, 
and a desire to target it therapeutically [4, 39], 
HuHMFG1 was selected as the optimum antibody to 
take forward for therapeutic development over CT2 as 
the latter is not as suitable for ADC development due to 
its intracellular location. Since it was shown HuHMFG1 
bound some normal epithelium, development as a 
photoimmunoconjugate was chosen as the use of light 
to selectively activate the drug in a local area could be 
used to avoid the majority of normal epithelium which 
can be distinguished endoscopically.
HuHMFG1 staining at the optimized concentration 
was sensitive (95% of cancers were identified as 
positive) but not specific (40% of normal tissue also 
stained positive). Specificity for HGD and EA could be 
demonstrated by using a less antibody (0% staining in 
Sq, NDBE and LGD) however this was at the expense of 
substantially reduced sensitivity (positive staining in HGD 
and EA fell to ~20%) (Supplementary Figure 3).
Staining of resection specimens demonstrated 
that HuHMFG1 does not bind normal connective tissue, 
vascular or muscular structures of the esophagus. The 
epithelial specificity of HuHMFG1 is demonstrated 
exquisitely in Figure 5 in which a whole esophagus 
transverse section taken from a patient with EA was 
stained with HuHMFG1. This section includes 2 lymph 
nodes, one infiltrated with cancer and one free of disease. 
HuHMFG1 selectively stains only the infiltrated node. 
To confirm this pattern in lymph nodes, staining was 
extended to a panel of 11 EA resection specimens with 
31 associated locoregional nodes. HuHMFG1 staining 
was positive in all 18 tumor infiltrated lymph nodes 
and negative in all 13 benign nodes (Fishers exact p 
<0.0001). This reinforces the choice for HuHMFG1 
for therapeutically application as any off target effects 
in normal areas would spare connective, muscular and 
vascular tissue and damaged normal squamous mucosa 
can regrow [40].
Figure 1: Gene set enrichment and microarray analysis of MUC1 in the progression to esophageal adenocarcinoma. 
Heat map A. and an example probability plot B. of the gene set enrichment analysis (GSEA) for non-dysplastic Barrett's esophagus 
(NDBE) vs normal squamous esophageal epithelium (Sq). Heat map C. and an example probability plot D. of the GSEA for esophageal 
adenocarcinoma (EA) vs Sq. GSEA detail in supplementary (Supplementary Figure 1) and evaluated with Kolmogrov-Smirnoff test. 
Microarray analysis E.; raw expression values of MUC1 mRNA in Sq, NDBE and EA tissues, results show a 2.3 fold increase in MUC1 
expression at the mRNA level in NDBE compared to Sq (Mann-Whitney; p < 0.001) and 2.2 fold increase in EA compared to Sq (Mann-
Whitney; p = 0.03). Box plot presented as median and interquartile range.
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Figure 2: Representation of MUC1 receptor structure in normal and tumor epithelium with binding sites for selected 
antibodies. Representation of MUC1 receptor glycosylation in normal and tumor epithelium. NCL-MUC1 binds a sialic acid on the 
glycosylated side chain, while NCL-MUC-1-CORE and HuHMFG1 bind the extracellular peptide backbone. The extracellular target 
antigens can be hidden in fully glycosylated normal tissue, but become increasingly exposed in cancer due to aberrant glycosylation. CT2 
targets the intracellular cytoplasmic tail of MUC1.
Figure 3: Immunohistochemical staining patterns with anti-MUC1 antibodies in high grade dysplasia and HuHMFG1 
staining in the squamous-metaplasia-dysplasia-carcinoma sequence. A. Immunohistochemical images of high-grade dysplasia 
in Barrett’s epithelium stained with four anti-MUC1 antibodies (brown), and hematoxylin (blue). B. HuHMFG1 staining in normal 
esophageal squamous epithelium (Sq), non-dysplastic Barrett's esophagus (NDBE), low-grade dysplasia (LGD), high grade dysplasia 
(HGD) and invasive esophageal adenocarcinoma (EA). An increase in the intensity of staining is seen as pathological grades progress. 
Staining also follows the direction of epithelial maturation from basement membrane toward the lumen. In higher pathological grades, 
staining is seen throughout the epithelial layer.
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Figure 4: Levels of expression of four MUC1 epitopes in the squamous-metaplasia-dysplasia-carcinoma sequence. 
A. The anti-MUC1 antibodies HuHMFG1, CT2, NCL-MUC-1 and NCL-MUC-1-CORE were evaluated by immunohistochemistry in 
esophageal tissue from incremental pathological grades including normal squamous epithelium (Sq), non-dysplastic Barrett's esophagus 
(NDBE), low-grade dysplasia (LGD), high grade dysplasia (HGD) and invasive esophageal adenocarcinoma (EA). Positivity was defined by 
2+/3+ intensity staining in ≥10% of the pathology examined. The proportion of positive samples for each tissue is shown with respectively 
colored polynomial lines of best fit. HuHMFG1 and CT2 staining increase at the metaplastic (NBDE) stage, whereas NCL antibodies 
increase staining after development of EA. B. All antibodies showed significant expression differences during progression to cancer (χ2 
test; p < 0.00005), with all having a significant trend of increasing positivity (Pearson’s R; p < 0.001).
HuHMFG1 potential as a therapeutic antibody 
in living cells
To confirm binding to native antigen in living cells, 
HuHMFG1 was tested in vitro on a panel of esophageal 
cell lines derived from each stage in the squamous-
metaplasia-dysplasia-carcinoma sequence. All EA lines 
showed a dose dependent increase in cell binding of 
HuHMFG1 to a point of cell surface receptor saturation; 
HuHMFG1 binding was at a low level in normal 
squamous cells (Het1A) but then incrementally increased 
through NDBE cells (BAR-T), HGD cells (chTERT) 
with the highest level of binding seen in EA cells (OE19) 
(Figure 6).
For an effective ADC, it is preferable but not 
required that it underwent intracellular internalization 
after binding. Using confocal microscopy, internalization 
of HuHMFG1 into an EA cell line (OE19) was shown 
(Figure 6). The punctate intracellular pattern is similar to 
the pattern seen in previous work where endosomal co-
localization of HuHMFG1 was demonstrated in a breast 
cancer cell line [21].
To prove the targetable therapeutic potential of 
HuHMFG1, an ADC of the antibody was made via NHS 
ester mediated amide conjugation of photosensitive drug 
molecules (PS1) to available lysine amino acids [41, 42]. 
UV-VIS spectrometry of the final HuHMFG1:PS1 ADC 
dissolved in PBS confirmed peak absorption at 683nm for 
laser activation and approximately 7 PS1 photosensitizers 
were coupled on average onto each HuHMFG1 antibody 
(Figure 7). Digital image analysis of reducing SDS-PAGE 
separation of the conjugate indicated 52% of the PS1 was 
conjugated to HuHMFG1 via a covalent amide bond, 
and 48% was conjugated via non-covalent interactions. 
The non-covalent material in the conjugate was tightly 
bound and not dissociated in biological buffers or with 
the addition of low level detergent during the purification 
process. Upon conjugation small shifts in the absorbance 
spectra of PS1 were observed; the two main PS1 peaks at 
398nm and 687nm shifted 4-5nm into the blue, and the 
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ratio between the two main peaks changed from 2.2 in 
the free PS1 to 2.6 in the conjugated form. There were 
no shifts in absorbance observed between the free and 
conjugated antibody at 280nm (Figure 7).
Confocal microscopy was used to confirm 
HuHMFG1:PS1 ADC internalization into OE19 cells. 
Both the drug (PS1) and antibody (HuHMFG1) parts of 
the conjugate remain co-localized after internalization 
in a similar pattern to that seen with unconjugated 
HuHMFG1 (Figure 7). Due to the photoactive nature of 
the drug, carrying out live cell imaging induces cell death. 
In an attempt to co-localize the ADC with a marker of 
endosomal localization, a nontoxic ADC was produced 
using the same reaction conditions but in which non-
toxic Cy5.5 dye molecules were covalently conjugated to 
HuHMFG1 instead of PS1. Spectral analysis of the new 
HuHMFG1:Cy5.5 ADC show the antibody had an average 
of 5 dye molecules covalently bound per antibody and 
when run on SDS PAGE, the conjugate showed 30% non-
covalently bound Cy5.5 (data not shown). Results showed 
partial co-localization of the HuHMFG1:Cy5.5 conjugate 
with transferrin a marker of the recycling endosomal 
pathway. This could suggest HuHMFG1 conjugates are 
internalized during endocytosis but then delivered to 
another compartment, i.e. the lysosome compartment 
(Figure 7).
The phototoxic ADC HuHMFG1:PS1 was 
investigated for its light dependent cytotoxicity with an 
in vitro MUC1 positive EA cell line. OE19 cells were 
incubated in the dark with a range of doses of either 
Figure 5: HuHMFG1 staining MUC1 in invasive esophageal adenocarcinoma and locoregional lymph node metastases. 
A. A transverse esophagectomy section from a patient with invasive esophageal adenocarcinoma (EA) stained with HuHMFG1 (brown) and 
hematoxylin (blue). HuHMFG1 stains surface mucin, invasive EA as it invades into muscularis externa and only the local tumor infiltrated 
lymph node. Normal mucosa and a benign local lymph node did not stain positively. A x20 magnification from a representative tumor 
region is inset. B. Analysis of 31 locoregional nodes resected from 11 patients highlight positive expression of MUC1 by HuHMFG1 in all 
malignant but no benign lymph nodes (Fishers exact; p <0.0001).
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HuHMFG1:PS1 or the equivalent concentration of free 
PS1 molecules. Cells were then washed and either left 
in the dark or irradiated with low intensity laser light at 
670nm [0.33J/cm2 over 10seconds] (Figure 8A). Despite 
the non-covalently bound material, light-dependent 
cytotoxicity of the HuHMFG1:PS1 ADC was seen to 
be significantly more potent than equivalent amounts 
of PS1 alone (linear regression p=0.0022, F=26.09). No 
significant cytotoxicity was seen with either drug in the 
dark (linear regression p=0.7335, F=0.1273) or between 
the vehicle control (2% DMSO) and cells in media only 
(p=0.12) (data not shown). The top HuHMFG1:PS1 dose 
was then used to compare cytotoxicity in MUC1 positive 
OE19 cells to a MUC1 negative cell line HT29 (Figure 
8B). The phototoxic efficacy of the HuHMFG1:PS1 ADC 
was significantly greater in MUC1 positive OE19 cells 
than negative HT29 cells (t test p<0.0006). No cytotoxicity 
was seen in either line with the unconjugated antibody or 
with the ADC in the absence of light.
DISCUSSION
GSEA looks at cellular pathways focusing on 
groups of genes that share common biological function, 
chromosomal location, or regulatory pathways. GSEA 
found MUC1 was identified as a protein involved 
with, and up-regulated in, the progression from normal 
squamous epithelium to invasive EA. To confirm the 
GSEA results, and to clarify some of the variations in 
MUC1 IHC profiles previously reported in the literature, 
4 different antibodies recognizing different epitopes of 
MUC1 were tested in a panel of human biopsy samples.
Figure 6: MUC-1 expression in esophageal cell lines of various pathological grades and internalization into esophageal 
adenocarcinoma. A. Binding of the antibody HuHMFG1 in vitro to esophageal cell lines originally isolated from tissue of various 
pathological grades was carried out using flow cytometry. Cells were incubated with varying concentrations of HuHMFG1 antibody which 
was detected using a FITC conjugated anti-human IgG secondary fluorescent antibody (shown in green) shown alongside nuclei staining 
with DAPI (shown in blue). An increase in fluorescence represents more HuHMFG1 bound to each cell and the saturation of the fluorescent 
signal indicates cell surface receptor saturation. HuHMFG1 did not bind the colonic line HT29 (negative control). It bound at a low level 
in normal squamous and non-dysplastic Barrett’s esophagus (NDBE) and a high level in high grade dysplasia (HGD) and esophageal 
adenocarcinoma (EA). B. Confocal microscopy images showing OE19 cells exposed to HuHMFG1 (i) or media alone (ii). OE19 internalize 
HuHMFG1 and the intracellular localization pattern is punctate.
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The NCL-MUC-1-CORE antibody binds directly 
to the VNTR protein backbone where normal mucin 
glycosylation levels sterically hinder antibody binding. 
Sagara and colleagues had similar findings with a 
different MUC1 backbone binding antibody (DF3). They 
too showed it did not bind normal squamous esophageal 
epithelium [43]. Strong binding of this antibody in EA is 
most likely due to a tumor associated MUC1 reduction 
Figure 7: Photophysical characterization and internalization of photoactive MUC1 targeting antibody drug conjugates. 
A. Absorbance spectra of HuHMFG1:PS1 antibody drug conjugate (ADC) highlights peak absorbance at 683nm (red spectral region) for 
laser excitation. Shown are any photophysical shifts away from the absorbent spectra of free antibody or free PS1 (spectra normalized to 
280nm or 687nm respectively). B. SDS page gel showing proportion of covalently coupled antibody to free photosensitizer (PS1) in the 
ADC mixture; (i-iii) Coomassie stained protein gel; (i) molecular weight markers, (ii) HuHMFG1 and (iii) HuHMFG1:PS1 ADC. (iv-vi) 
Image of the same SDS gel before Coomassie staining for the PS1 dye via UV fluorescence; (iv) molecular weight markers, (v) HuHMFG1 
and (vi) HuHMFG1:PS1 ADC. Covalently bound photosensitizer PS1 is that seen at the same height as antibody protein. C. Confocal 
microscopy images showing OE19 cells exposed to HuHMFG1 and PS1 in either a conjugated form or free un-conjugated form showing 
the covalently bound photosensitizer and antibody components remain co-localized after internalization. HuHMFG1 (in green) nuclei 
staining (in blue) PS1 (in red). D. HuHMFG1 was conjugated to a non-toxic dye Cy5.5 and OE19 cells exposed to the HuHMFG1:Cy5.5 
conjugate with and without a marker of recycling endosomal localization. Cells were co-stained with the nuclear stain DAPI shown in 
blue. Cy5.5 fluorescence is shown in red, endosomal marker is shown in green and the partial co-localization of HuHMFG1 and endosomal 
marker is shown in yellow.
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in glycan chain length and density similar to that seen 
in breast cancer [44]. NCL-MUC-1 showed a similar 
binding pattern to NCL-MUC-1-CORE.NCL-MUC-1 
binds a sialylated amino acid attached to a carbohydrate 
linked to the peptide backbone and like NCL-MUC-
1-CORE this epitope was shown to be either exposed 
or upregulated much later in the progression pathway. 
Other mucin associated Sialyl-Tn antigens have similarly 
been associated with the final stages of malignant 
transformation in squamous cell esophageal carcinoma 
[45]. Quantification of these antibodies reflects staining 
intensity and the amount of antibody bound. With MUC1 
Figure 8: Light dependent cytotoxicity and superior efficacy over equivalent free photosensitizer of a MUC1 specific 
photoactive antibody drug conjugate. A. The cytotoxicity of HuHMFG1:PS1 ADC, was compared with equivalent free photosensitizer 
(PS1) concentrations in light and dark conditions in OE19 cells. Light activation was by laser at 0.33J/cm2 at 670nm over 10 seconds. 
Light activated ADC cytotoxicity was significantly more effective than light activated PS1 cytotoxicity (linear regression of dose response 
curves with F test for comparison; p=0.0002; F=26.09). B. The cytotoxic efficacy of HuHMFG1:PS1 ADC, HuHMFG1 antibody alone and 
vehicle control were compared in a MUC1 positive line (OE19) and a MUC1 negative line (HT29) with and without light activation. Light 
activation involved an energy exposure of 0.33J/cm2 at 670nm over 10 seconds. Light activated ADC cytotoxicity was significantly more 
effective in the MUC1 positive line compared to the MUC1 negative control (Students t-test; p=0.0006). No significant cytotoxic effect was 
seen in either line with the vehicle control, antibody alone or ADC without light activation.
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this staining intensity will not correlate with MUC1 
expression at the molecular level, this is due to variation 
in the number of tandem repeats between individuals [46]. 
Though variation does exist, for the purpose of clinical 
translation we expect MUC1 will follow the example 
set by Trastuzumab in HER2 positive esophagogastric 
cancer and use a similar IHC staining intensity cut-off to 
identify which individuals would respond well to antibody 
treatment [5].
HuHMFG1 and CT2 demonstrate persistently high 
levels of binding in all pathological grades from NDBE to 
EA making them suitable for ADC development for early 
and locally advanced esophageal neoplasia. CT2 is an 
intracellular epitope so further development was focused 
on HuHMFG1. Though HuHMFG1 bound a proportion of 
normal epithelium, its specificity to the epithelial layer is 
important therapeutically. Damaged mucosa can re-grow 
but serious damage occurs when therapy reaches deeper 
muscle layers and can cause esophageal strictures [23, 47]. 
Re-epithelialization with neosquamous epithelium is likely 
to follow HuHMFG1 treatment strategies in pre-invasive 
disease, similar to regeneration seen following ablative 
esophageal therapies [4]. HuHMFG1 also offers potential 
to treat a selection of established invasive cancers, 
including those with locoregional lymph node spread, 
particularly if a photosensitizing drug is used which is 
activated by deep red light. At 670nm, light penetrates 
more deeply into tissue than at 633nm, used to activate 
first generation PS such as porfimer sodium. Under 
optimal conditions, depth of necrosis can also extend 
up to five times the light penetration [48]. In bladder 
tumors, 673nm light penetrates 5.03mm to create PDT 
effect up to 25mm from the urothelial surface [49]. When 
administered into the lumen of the esophagus, a similar 
depth of PDT effect is envisaged allowing for treatment of 
locally infiltrated lymph nodes.
HuHMFG1 was shown to bind a panel of living 
esophageal cells throughout the pathological grades in 
a similar pattern to that observed with IHC. To provide 
proof-of-concept of HuHMFG1 as an ADC a conjugate 
with a photoactive-drug was produced. Photodynamic 
therapy (PDT) is particularly relevant for EA as laser light 
is easily applied via endoscopy. Targeting photosensitizers 
with HuHMFG1 would improve PDT selectivity. PS1 
(previously developed as compound 1) is a second 
generation photosensitizer based on the chlorophyll 
derivative PPa. It has been chemically manipulated to 
include a bioconjugation handle and a series of short 
PEG-like chains to increase its water solubility [41]. PS1 
was conjugated to HuHMFG1 via NHS mediated amide 
bond formation to exposed lysine amino acid residues. 
The ADC produced was shown to contain an average of 7 
PS1 molecules per antibody but around half of these were 
non-covalently bound. Since the method for estimating 
conjugation ratio uses extinction coefficients based on the 
absorbance spectra of the free PS1 dye, the small shifts 
in absorbance upon conjugation may compromise the 
validity of the resulting ratio. Further work would have 
to be done to address this before the ADC is taken further. 
The additional non-covalently bound material is a problem 
seen elsewhere with PDT-ADCs and would hinder further 
development as it stands. It would likely cause batch-to-
batch inconsistencies and make for poor chemical and 
biological reproducibility alongside a loss of selectivity 
of the final product [50]. Despite some of the PS1 being 
non-covalently bound, the photosensitizer and antibody 
seem to remain co-localized in vitro. The intracellular 
localization of the photoimmunoconjugate is critical to 
the mechanism of action and would rather be established 
more fully and where possible done with the final drug, 
not a non-toxic equivalent as we have shown, if this was to 
be taken further. For future translation we plan to improve 
purity by using smaller antibody fragments with optimized 
lysine spacing and an alternative conjugation strategy 
with more hydrophilic PS. This would have advantages 
from a pharmacokinetic and manufacturing point of view 
[33]. We have successfully applied this technique using a 
HER2 targeting antibody Fab fragment [51]. We believe 
despite these issues with purity, the cytotoxicity results 
presented offer a promising proof of concept for a MUC 
targeted ADC. A low dose of laser light, only 0.33J/cm2, 
was used to make it translatable to the lower level of light 
that can be clinically delivered deeper into tissue. The 
wavelength of light used was 670nm and so use of a laser 
closer matched to the peak absorbance of PS1 (Figure 7) 
would hopefully improve cytotoxicity. HuHMFG1:PS1 
demonstrated light dependent cytotoxicity that was 
significantly more effective for both the MUC1 positive 
cell line than for the MUC1 negative cell line and more 
potent than equivalent free PS1 photosensitizer.
This paper confirms how MUC1 is upregulated 
during progression with gene set enrichment analysis, 
immunohistochemistry and flow cytometry in esophageal 
tissues and cell lines taken from discrete histological 
grades. It clarifies previously conflicting data with regards 
to the detection of epitopes differentially expressed on 
MUC1 due to glycosylation changes. It shows how MUC1 
expression is maintained by glandular cells throughout 
the metaplasia-dysplasia-carcinoma sequence, binding 
only the epithelial layer in early disease. In advanced 
disease, expression is maintained by glandular cells as 
they invade the submucosa, muscular layer and into 
metastases. HuHMFG1 was shown to positively bind a 
high proportion of cases from non-dysplastic Barrett’s 
epithelium, through degrees of dysplasia to invasive EA. 
This suggests HuHMFG1 may have excellent therapeutic 
potential. To confirm this, we showed HuHMFG1 binding 
in live cells and developed first in class proof-of-concept 
MUC1 targeting photoactive ADCs. We postulated on 
its therapeutic mechanism and confirmed its cytotoxic 
efficacy for the future translation of this antibody into the 
clinical arena.
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MATERIALS AND METHODS
Gene set enrichment analysis
Microarray data was obtained from Gene Expression 
Omnibus data from Wang et al [52]. The data set included 
19 normal esophageal squamous epithelium, 20 NDBE 
and 21 EA samples. Gene set enrichment analysis was 
carried out as previously described on around 4000 
cellular pathways using the Kolmogrov-Smirnoff test 
[53]. Recurrent genes in the most important pathways in 
transition from squamous to NDBE and squamous to EA 
were identified. The MUC1 gene probe 213693_s_at was 
then used to mine additional gene expression microarray 
data [52, 54–56] for raw mRNA expression levels using 
Affymetrix, and compared with Mann-Whitney test.
Tissue panel
A panel of formalin fixed paraffin embedded (FFPE) 
esophageal specimens of varying pathological grades was 
identified from the University College London Hospital 
upper gastrointestinal clinical database. The pathology 
sample chosen was of the highest grade the patient had at 
the time of sampling. Ethical approval was obtained from 
the UK Research Ethics Committee (EC13.13; 08/H808/8; 
08/H0714/27). Esophageal tissue samples were selected 
from 123 patients containing, in order of disease severity; 
normal squamous tissue (n=15), NDBE (n=29), low 
grade dysplasia (n=25;), high grade dysplasia (n=34) and 
invasive EA (n=20). Sections from selected samples were 
stained with Hematoxylin and Eosin (H&E) to confirm the 
reported pathological grade by two expert GI pathologists 
(MN, MRJ). H&E staining was performed using standard 
protocols.
Immunohistochemistry
In order to examine MUC1 glycoprotein expression 
during progression to EA, four antibodies against 
distinct areas and/or glycoforms were tested. The mouse 
monoclonal antibody NCL-MUC1 binds a sialylated 
amino acid attached to a carbohydrate linked to the 
PDTRPAP region of the VNTR [57]. The humanized 
monoclonal antibody HuHMFG1 binds a glycan linked 
PDTR amino acid sequence on the VNTR [58]. The mouse 
monoclonal antibody NCL-MUC-1-CORE binds directly 
to the TRPAPG amino acid sequence on the VNTR 
[57]. The hamster monoclonal antibody CT2 targets 
the intracellular SSLSYTNPAVAATSANL amino acid 
sequence on the cytoplasmic tail of MUC1 [59] Binding 
of antibodies to the antigens near or on the VNTR can be 
sterically hindered in fully glycosylated normal MUC1, 
but become increasingly exposed in cancer due to aberrant 
glycosylation [60] [61] (Figure 1).
Immunohistochemical (IHC) techniques were 
optimized to maintain strongly positive tissue staining 
in the absence of background staining with antibodies 
at the following primary concentrations. NCL-MUC-1 
(1:500; Leica-Novocastra), HuHMFG1 (1:1000 [10μg/
mL]; Antisoma, UK) NCL-MUC-1-CORE (1:500; Leica-
Novocastra) and CT2 (1:500; gifted by Professor Sandra 
Gendler, Mayo Clinic, USA). Staining was carried out 
using heat-induced epitope retrieval in pH 6.0 sodium 
citrate buffer (Sigma-Aldrich, S4641). Endogenous 
peroxidase (Leica, RE7157) and non-specific protein 
activity (Leica, RE7158) were blocked prior incubation 
with primary antibody. The humanized antibody 
HuHMFG1 required initial biotinylation (ThermoFisher, 
21335) followed by incubation with ExtrAvidin 
Peroxidase (Sigma-Aldrich E2886). All other slides were 
incubated with post-primary block (Leica RE7159) and 
polymer (Leica RE7161). Slides were then developed with 
3,3-diaminobenzadine tetrahydrochloride as a chromogen 
(Leica RE7162), counterstained with hematoxylin, 
dehydrated in graded ethanol and mounted in distyrene 
plasticizer xylene (Sigma Aldrich 06522).
All slides were scored by two expert GI pathologists 
(MN, MRJ). Positive MUC1 cases were defined as 
those staining 2+/3+ intensity in ≥10% of the pathology 
examined, following the established classification 
adopted for HER2 [5]. The Allred system was also 
used to characterize staining in more detail. Intensity 
was scored as negative (0), mild (1), moderate (2+) and 
strong (3+), and proportion of tissues positively stained 
as negative (0), <1% (1), 1-<10% (2), 10-<33% (3), 33-
<66% (4) and ≥66% (5) [62]. Statistical tests including chi 
squared, Pearson's R and Linear regression analysis were 
performed using IBM® SPSS® statistics Version 22 (IBM 
Corporation).
Cell culture
Het1A obtained from ATCC (October 2014) is 
a human cell line established from an area of normal 
esophageal epithelium that has been SV40 large T 
antigen-immortalised [63, 64]. BAR-T gifted by Prof 
Rhonda Souza (UT Southwestern, USA) is a human 
cell line established from an area of non-neoplastic 
Barrett’s that has been telomerase-immortalised [65]. 
ChTERT (CP-52731) gifted by Dr Stuart McDonald 
(Barts Cancer Institute, UK) is a human epithelial cell line 
established from an area of high grade dysplastic Barrett’s 
esophagus that has also been telomerase-immortalised 
[66]. OE19, obtained from the ECACC (May 2014) is a 
human epithelial cell line established from a stage three 
moderately differentiated esophageal adenocarcinoma 
at the esophageal gastric junction [67]. These cells were 
compared to human Caucasian colon adenocarcinoma cell 
line (HT-29) gifted by Prof Marilena Louzidou (Royal 
Free Hospital, UK) as a negative control, as it does not 
bind HuHMFG1. All lines were cultured either according 
to ECACC/ATCC guidelines or their original publication. 
All cells were confirmed mycoplasma free.
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Flow cytometry
Cell lines were detached with Accutase (Millipore 
SCR005) or a 0.05%Trypsin/0.02% EDTA/0.5%PVP 
solution for Het1A cells. Approx. 200,000 cells per 
sample were washed and incubated in 50ul on ice 
with varying concentrations of HuHMFG1. After 1 
hour cells were again washed and exposed to 300nM 
α-Human IgG (FAB specific) FITC conjugate (Sigma-
Aldrich F5512) on ice for 30 minutes before two final 
washes. All steps carried out in FC buffer; PBS + 2% 
FCS + 1mM EDTA. Flow cytometry was carried out on 
a Beckman-Coulter Cyan ADP, Cells underwent laser 
excitation at 488nm and emission was recorded between 
510nm and 550nm.
Confocal microscopy
OE19 cells were plated in a Lab-Tek 8 well 
chambered borosilicate cover glass (NUNC 155411) 
at 10,000 cells/well and cultured at 37°C / 5%CO2. 
Figure 6= Cells were cultured for 4hrs in media with 
and without 0.5μM HuHMFG1. Figure 7C= Cells 
were cultured for 2.5hrs in media with either 0.5μM 
HuHMFG1:PS1 in the ADC conjugated form or 0.5μM 
unconjugated HuHMFG1 plus the equivalent amount of 
free PS1 that was present in the ADC. Figure 7D= Cells 
were cultured for 5hrs with 0.3μM HuHMFG1:Cy5.5 
with or without additional 0.3uM Transferrin Alexa 
Fluor 488 (Molecular Probes, Life Technologies). 
Cells were then fixed with 4% formaldehyde (VWR 
361387P) in PBS, permeablized with 0.1% Triton X-100 
(Sigma-Aldrich X100) and blocked with 0.05% Triton 
X-100, 4% goat serum (Sigma-Aldrich G6767) and 1% 
bovine serum albumin (Sigma-Aldrich 9418) in PBS. 
HuHMFG1 was labelled with 0.098 mg/ml of anti-human 
IgG FITC (Sigma F5512), 0.05% Triton X-100 and 4% 
goat serum. Cells were then washed and co-stained 
with 300nM 4',6-Diamidino-2-Phenylindole, Dilactate 
(DAPI) (Invitrogen D3571) in a mounting media 
made up from 0.5% N-Propyl gallate (Sigma-Aldrich 
P3130), 50% glycerol (VWR 24388.295) in 20mM Tris 
(Sigma-Aldrich T1503) pH 8. Images were collected 
at x63 magnification on a Perkin Elmer Spinning Disk 
Microscopy system using Volocity image acquisition 
software. FITC or Alexa Fluor 488 fluorescence was 
collected with excitation at 488nm and detection 
between 500 and 555nm and is shown in green. DAPI 
fluorescence was collected with excitation at 405nm and 
detection between 580 and 650nm and is shown in blue. 
PS1 or Cy5.5 fluorescence was collected with excitation 
at 640 nm and detection between 485-705 nm and is 
shown in red. Single stain control wells were included in 
the experiments and no bleed through was seen for any 
of the dyes/channels (data not shown).
Production and characterization of 
HuHMFG1:PS1
N-Hydroxysuccinimide activated PS1 (PS1-
NHS) was produced as previously published [41] and 
patented [42]. Small volume aliquots of PS1-NHS or a 
commercially available Cy5.5 NHS Ester (Amersham, 
GE Healthcare) were dissolved in DMSO were added 
progressively into a light protected PBS pH7.4 mixture 
containing 16.7μM HuHMFG1 and organic solvents 
at a final concentration of 20% DMSO and 6% MeCN, 
PS1-NHS or Cy5.5-NHS was added until 16 times molar 
excess over the protein. The reaction was left shaking 
and protected from light at room temperature for 2 hours. 
The resulting conjugates were dialyzed extensively into 
PBS pH 7.4 through a cellulose membrane with pore size 
MWCO 7kDa (Slide-A-Lyzer Dialysis Cassettes, 66370, 
Pierce), to remove unreacted or hydrolyzed PS1 as well 
as any organic solvents, neither gentle dialysis with a 
larger MWCO or size exclusion chromatography in the 
presence of low detergent concentrations were sufficient 
to improve the purity. For UV-VIS analyses a sample was 
diluted to a suitable concentration into PBS in a micro 
volume 1 cm path length quartz cuvette and absorbance 
was measured over 190-400nm on an Agilent 8453 UV 
Visible Spectrophotometer (Agilent Technologies). 
Spectra were normalized to 900 nm and PBS background 
removed. Concentrations were calculated using the 
following equation A = εlc where A is absorbance of 
the sample, ε = molar absorptivity, l = path length in cm 
and c = concentration in molar. Before spectra could be 
used to calculate conjugation efficiency, Molar extinction 
coefficient (M−1 cm−1) and the peak absorption were 
calculated for the free dyes in PBS and used as follows 
PS1 (A280=8896, A687=20594) and Cy5,5 (A280=22479, 
A674=215826), a generic IgG molar extinction coefficient 
was used for HuHMFG1 (A280=210000). To calculate 
conjugation ratio; absorbance of the conjugate at its peak 
absorbance in the red (678nm or 674nm) was used to 
obtain the concentration of the dye in the conjugate, this 
concentration could be used to calculate the contribution 
of the dye to absorption at 280nm. The remaining A280 
is then attributed to the antibody and can be used to 
calculate the protein concentration. For reducing SDS 
analysis a sample of the conjugate was then denatured in 
reducing Laemmli Loading buffer that does not contain a 
loading dye, and run through on 12% Acrylamide SDS-
PAGE. Fluorescence of the wet gels was visualized by 
exciting the photosensitizers with a UV-transilluminator 
(Fujifilm-LAS3000). Gels were then stained with 
Coomassie Brilliant Blue to visualize protein. Image 
analysis techniques of the unstained gel images were used 
to estimate the proportion of covalently coupled to free 
photosensitizer in the immunoconjugate mixture using 
AIDA image Analyzer software v3.52.
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Cytotoxicity studies
The cytotoxic efficacy of the HuHMFG1-PS1 ADC 
was compared with both equivalent concentrations of free 
HuHMFG1, and free equivalent PS1 in the presence or 
absence of laser “light” activation. MUC1 positive OE19 
cells and MUC1 negative HT29 cells were plated in black 
walled 96 well plates and allowed to adhere over 24 hours. 
Cells were incubated at 37°C / 5% CO2 in the dark with 
various doses of HuHMFG1, PS1 or HuHMFG1:PS1 
ADC in supplemented cell culture media without phenol 
red (Sigma-Aldrich R7509) plus 2% DMSO. Controls 
included triton X 100 (100% cell death), culture media 
with 2% DMSO (vehicle control) and media alone with 
and without cells. After 2 hours cells were washed and 
returned to normal media and left at 37°C / 5% CO2 for 
a further hour. Where cells were irradiated laser light 
was delivered at 670nm [0.33J/cm2 over 10seconds] 
(HPD 7401 laser system, High Power Devices Inc). Dark 
controls were not lasered. Cell viability was measured 
48 hours later with MTS assay (Promega Cell Titre-96) 
via absorbance at 490nm. Background absorbance was 
removed using cells that had been lysed using triton X 100 
and % cell viability was calculated using the cells in media 
only. Cytotoxicity between cell types was compared using 
the Students T-Test (Microsoft Excel). Dose response 
curves comparing cytotoxicity of HuHMFG1:PS1 ADC 
versus equivalent PS1 alone in light and dark were 
compared using linear regression analysis assigning best 
fit curves on a log scale (GraphPad PRISM ®).
Transcript profiling
GEO accession numbers: GSE26886, GSE1420, 
GSE13083, GSE19529.
Ethics
Ethical approval was obtained from the UK 
Research Ethics Committee (EC13.13; 08/H808/8; 08/
H0714/27).
Abbreviations
ADC (antibody drug conjugate); BE (Barrett’s 
epithelium); EA (esophageal adenocarcinoma); FFPE 
(formalin fixed paraffin embedded); GSEA (gene set 
enrichment analysis); H&E (haematoxylin and eosin); 
HER2 (human epidermal growth factor receptor 2); HGD 
(high grade dysplasia); IHC (immunohistochemistry); 
LGD (low grade dysplasia); MUC1 (mucin glycoprotein 
1); NDBE (non-dysplastic Barrett’s esophagus); PBS 
(phosphate-buffered saline); PDT (photodynamic therapy); 
PS (photosensitizer); SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis); Sq (squamous); UV-
Vis (ultraviolet–visible spectroscopy); VNTR (variable 
number tandem repeat).
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